Industry News

NPF awards six research grants to scientists studying psoriasis and psoriatic arthritis

NPF awards six research grants to scientists studying psoriasis and psoriatic ar

The National Psoriasis Foundation (NPF) has awarded six research grants totaling $450,000 for projects that aim to discover new treatments and a cure for these chronic diseases.
Theoharis Theoharides, MD, PhD, professor of pharmacology at Tufts University School of Medicine in Boston, received a two-year, $200,000 translational research grant to translate his laboratory findings into real-world applications to manage health. Dr. Theoharides will explore how stress contributes to psoriasis and how molecules derived from chamomile might interrupt this psoriasis-stress connection.

Dermatologic surgeon launches ASDS Fundamentals Series videos

Kavita Mariwalla, MD

Kavita Mariwalla, MD, a private practice dermatologic surgeon and assistant professor at Stony Brook University in New York, has joined with the American Society for Dermatologic Surgeons (ASDS) to create a series of educational videos for residents and residency programs. The ASDS Fundamentals Series was developed to provide dermatology residents with high-quality, up-to-date didactic lectures on basic subjects in dermatologic surgery.

Sheldon Pinnell, MD, Receives Honorary Membership in the Society of Investigative Dermatology

Sheldon Pinnell, MD

Sheldon Pinnell, MD, J. Lamar Callaway Professor Emeritus of Dermatology and Chief Emeritus of the Division of Dermatology at Duke University, has received honorary membership in the Society for Investigative Dermatology at the International Investigative Dermatology meeting held in Edinburgh, Scotland. Dr. Pinnell has been researching new technologies to prevent skin cancer and photoaging for more than five decades.

Suneva Medical Announces Results of Its Pivotal ArteFill Acne Scar Study

Suneva Medical (, a privately held aesthetics company, has released the initial treatment results from its Pivotal acne scar study evaluating the safety and efficacy of it long-term dermal filler ArteFill to treat acne scars.
The randomized, double-blinded, multi-center, controlled study evaluated subjects to determine the safety and efficacy of ArteFill for the treatment of moderate-to-severe atrophic acne scars.

JUVEDERM VOLUMA XC Gains Favorable Review on Path to Approval

JUVEDERM VOLUMA XC Gains Favorable Review on Path to Approval

The U.S. Food and Drug Administration General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee has voted unanimously that the benefits of JUVEDERM VOLUMA XC—an injectable hyaluronic acid volume filler—outweigh the risks. The committee's recommendation, although not binding, will be considered by the FDA when making the final approval decision for JUVEDERM VOLUMA XC for cheek augmentation to correct age-related volume deficit in the mid-face. If approved by the FDA, Allergan anticipates launching the new filler in late 2013.

BoNT-A for Skin Disease

A growing body of research suggests that botulinum toxins have value for medical dermatology patients.
BoNTA for Skin Disease

Botox (Allergan, was first approved in 1989 to treat two medical conditions involving muscle spasm (blepharospasm and strabismus), but since its approval to treat glabellar lines in 2002, it has become much more widely known as a cosmetic drug. That may soon change as more and more research points to the efficacy of botulinum neurotoxin A (BoNT-A) in treating a wide range of skin diseases and conditions.